Aneuploidy and translocations are hallmarks of B-progenitor acute lymphoblastic leukemia (ALL), but many individuals with this cancer lack recurring chromosomal alterations. Here we report a recurring interstitial deletion of the pseudoautosomal region 1 of chromosomes X and Y in B-progenitor ALL that juxtaposes the first, noncoding exon of P2RY8 with the coding region of CRLF2. We identified the P2RY8-CRLF2 fusion in 7% of individuals with B-progenitor ALL and 53% of individuals with ALL associated with Down syndrome. CRLF2 alteration was associated with activating JAK mutations, and expression of human P2RY8-CRLF2 together with mutated mouse Jak2 resulted in constitutive Jak-Stat activation and cytokine-independent growth of Ba/F3 cells overexpressing interleukin-7 receptor alpha. Our findings indicate that these two genetic lesions together contribute to leukemogenesis in B-progenitor ALL.
Aneuploidy and translocations are hallmarks of B-progenitor acute lymphoblastic leukemia (ALL), but many individuals with this cancer lack recurring chromosomal alterations. Here we report a recurring interstitial deletion of the pseudoautosomal region 1 of chromosomes X and Y in B-progenitor ALL that juxtaposes the first, noncoding exon of P2RY8 with the coding region of CRLF2. We identified the P2RY8-CRLF2 fusion in 7% of individuals with B-progenitor ALL and 53% of individuals with ALL associated with Down syndrome. CRLF2 alteration was associated with activating JAK mutations, and expression of human P2RY8-CRLF2 together with mutated mouse Jak2 resulted in constitutive Jak-Stat activation and cytokine-independent growth of Ba/F3 cells overexpressing interleukin-7 receptor alpha. Our findings indicate that these two genetic lesions together contribute to leukemogenesis in B-progenitor ALL.
Chromosomal alterations are a hallmark of ALL, the most common malignancy of childhood, and include aneuploidy (hyperdiploidy and hypodiploidy) and recurring chromosomal translocations such as t(12;21) (ETV6-RUNX1), t(1;19) (TCF3-PBX1), t(9;22) (BCR-ABL1) and rearrangement of MLL 1 . These alterations are important events in leukemogenesis and influence patients' response to therapy. However, up to one-quarter of individuals with childhood ALL lack a recurring chromosomal alteration, and the genetic basis for disease in these cases is poorly understood.
To identify submicroscopic genetic alterations contributing to the pathogenesis of ALL, we previously conducted high-resolution profiling of DNA copy-number alterations and loss of heterozygosity using SNP microarrays. We identified multiple recurring genetic alterations targeting key cellular pathways, including lymphoid development, cell cycle regulation and tumor suppression 2, 3 . These alterations included a newly discovered deletion involving the pseudoautosomal region 1 (PAR1) of Xp22.3/Yp11.3 in 15 B-progenitor ALL cases lacking common chromosomal translocations. Notably, six of eight individuals with Down syndrome-associated ALL (DS-ALL) harbored this deletion.
To further characterize the PAR1 deletion, we expanded our analysis of DNA copy-number alterations and loss of heterozygosity to include 329 individuals with ALL, including 272 with B-progenitor ALL (22 of those with DS-ALL) and 57 with T-lineage childhood ALL (see Supplementary Table 1 for subject characteristics and Supplementary  Table 2 for a full listing of all DNA copy-number alterations). We identified the PAR1 deletion in 19 individuals with B-progenitor ALL (7%), including 12 of 22 (54.5%) of those with DS-ALL, all of whom lacked recurring translocations commonly associated with non-DS-ALL (Supplementary Table 3) . Notably, all ten DS-ALL-affected individuals with cytogenetic abnormalities commonly observed in DS-ALL [4] [5] [6] (gain of chromosome X in eight cases and deletion of chromosome 9p22 in two cases) had a PAR1 deletion.
The region of PAR1 deletion appeared identical in all cases (Fig. 1a) , involved at least three genes (P2RY8, SLC25A6 and IL3RA; Fig. 1b) and was confirmed by genomic quantitative PCR (Supplementary Table 4 ). The deletion was adjacent to the cytokine receptor genes CSF2RA and CRLF2, but owing to sparse probe coverage on the SNP array platform used (Fig. 1b) , we could not precisely define the extent of deletion using SNP array data alone.
To map the boundaries of deletion, we conducted array-based comparative genomic hybridization on two samples using a Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblastic leukemia
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volume 41 | number 11 | november 2009 Nature GeNetics l e t t e r s 1 million-feature oligonucleotide array with dense coverage of the region. We found that the PAR1 deletion extended from immediately centromeric (upstream) of CRLF2 exon 1 to P2RY8 intron 1 (Fig. 1b) . CRLF2 encodes cytokine receptor-like factor 2 (also known as thymic stromal lymphopoietin (TSLP) receptor), a lymphoid signaling receptor molecule that forms a heterodimeric complex with interleukin-7 receptor alpha (IL7R) and binds TSLP 7, 8 . P2RY8 encodes a purinergic receptor (P2Y, G-protein coupled, 8) that is expressed at high levels in many tissues, including leukemic cells 9 . A single case of rearrangement of P2RY8 to SOX5 has been reported in primary splenic follicular lymphoma 10 . These observations suggested that the PAR1 deletion results in a previously undescribed rearrangement involving P2RY8 and CRLF2.
RT-PCR confirmed the presence of chimeric transcripts juxtaposing the first, noncoding exon of P2RY8 to the entire coding region of CRLF2 in all affected individuals with PAR1 deletion who had available material for analysis, but none of the 50 affected individuals who lacked the deletion ( Fig. 1c and Supplementary Fig. 1 ). The fusion junction was identical in each case (Fig. 1d) . Quantitative RT-PCR analysis revealed increased P2RY8-CRLF2 expression in those with the PAR1 deletion (Supplementary Fig. 2 ). Moreover, we detected elevated cell surface expression of CRLF2 by flow cytometric analysis of cryopreserved leukemic cells (Supplementary Fig. 3) . A single individual with DS-ALL (DS-ALL-#14) had elevated CRLF2 mRNA levels, as assessed by real-time PCR, but lacked the deletion, suggesting an alternative mechanism of CRLF2 dysregulation. Rearrangements of the immunoglobulin heavy chain locus (IGH@) at 14q32.33 to CRLF2 have recently been reported in B-progenitor ALL 11 , and FISH analyses of interphase nuclei confirmed IGH@-CRLF2 rearrangement in subject DS-ALL-#14 ( Supplementary  Fig. 4) . Thus, 13 of the individuals with DS-ALL (60%) had genomic rearrangements resulting in dysregulated CRLF2 expression.
We next characterized the genomic breakpoints of the PAR1 deletion by long-template PCR of genomic DNA extracted from leukemic cells (Supplementary Figs. 5 and 6) . The deletion breakpoints were highly conserved and were located 3.4 kb upstream of CRLF2 exon 1 and 0.3-1 kb distal to P2RY8 exon 1 (Supplementary Fig. 5c ). Notably, we observed partly or fully conserved heptamer recombination signal sequences immediately internal to the deletion breakpoints and a variable number of nonconsensus nucleotides between the aligning sequences in each subject ( Supplementary Figs. 5c and 6 ). These data suggest that the PAR1 deletion arises as a result of aberrant activity of the antigen receptor recombinases encoded by the RAG recombinase-activating genes, a mechanism that has been implicated in the generation of other sentinel chromosomal rearrangements and deletions in ALL 3, 12 .
DS-ALL is characterized by the presence of activating JAK mutations in up to 28% of those affected, most commonly in the JAK2 pseudokinase domain at or around Arg683 (refs. [13] [14] [15] [16] . JAK1, JAK2 and JAK3 mutations have also been identified in 10% of high-risk B-progenitor ALL-affected individuals without Down syndrome 16 . In this cohort, we identified previously described and newly discovered JAK mutations in 11 individuals with B-progenitor ALL (4%), including 6 (27.2%) with DS-ALL (Supplementary Fig. 7 ). These included alterations in the JAK2 pseudokinase domain (R683G, n = 5; R683S, n = 2; and IR682RG, n = 1), JAK2 kinase domain (T875N and G861W, n = 1 each) and JAK1 pseudokinase domain (V658F, the homolog of JAK2 V617F). Moreover, we observed significant association between CRLF2 and JAK mutations. Nine affected individuals (45%) with CRLF2 alterations had JAK mutations, compared to two (0.6%) who were lacking CRLF2 lesions (Fisher's exact P < 0.0001; Table 1 and Supplementary Table 1 ). Although we previously identified an association between outcome and the presence of JAK mutations in high-risk pediatric ALL 16 , we observed no association between CRLF2 and/or JAK mutation status and outcome in DS-ALL (data not shown).
To validate the high frequency of CRLF2 and JAK mutations in DS-ALL, we examined a second cohort of 53 individuals with B-progenitor DS-ALL (Supplementary Table 5 ). Twenty-eight (52.3%) had the PAR1 deletion detected by genomic PCR (Supplementary Fig. 8a ). In those for whom appropriate sample material was available, the deletion was associated with elevated CRLF2 expression on microarray analysis (Supplementary Fig. 9 ) and expression of P2RY8-CRLF2 (Supplementary Fig. 8b ). Moreover, eight individuals (27.6%) with the PAR1 deletion had JAK2 mutations, compared to one (4.2%) without the PAR1 deletion (Fisher's exact P = 0.02), again highlighting the strong association between CRFL2 overexpression and activating JAK2 mutations. 
l e t t e r s
The co-occurrence of CRLF2 and JAK mutations suggested that these events cooperate in leukemogenesis. To examine this hypothesis, we assessed the effect of P2RY8-CRLF2 and Jak mutations on the ability of the cytokine-dependent mouse B-progenitor Ba/F3 cell line to grow in the absence of exogenous cytokine. Jak mutations are usually insufficient on their own to transform Ba/F3 cells, but they render the cells growth factor-independent when coexpressed with erythropoietin or thrombopoietin receptors 13, 15, 16 . As CRLF2 normally forms a heterodimeric complex with IL7R, we expressed IL7R in Ba/F3 cells (Ba/F3-IL7R cells). Expression of P2RY8-CRLF2 or Jak2 mutants alone (either Jak2 R683G or the kinase domain alteration P933R 16 ) in the Ba/F3-IL7R cells did not induce cytokine-independent growth.
In contrast, coexpression of P2RY8-CRLF2 and Jak mutants resulted in constitutive Jak-Stat activation and cytokine-independent growth in Ba/F3-IL7R cells (Fig. 2a,b and Supplementary Figs. 10 and 11) . Moreover, this transformation was attenuated by pharmacological Jak inhibition (Fig. 2c) and knockdown of CRLF2 expression by short hairpin RNA (shRNA; Fig. 2d and Supplementary Fig. 12) .
Together, these data describe a recurrent intrachromosomal deletion of PAR1 of Xp22.3 and Yp11.3, which results in the generation of chimeric P2RY8-CRLF2 mRNA and markedly elevated expression of CRLF2. CRLF2 overexpression from IGH@-CRLF2 rearrangement or PAR1 deletion has also been reported in B-progenitor ALL 11 . However, CRLF2 alteration is uncommon in B-progenitor ALL (5% of affected individuals), whereas it is present in over 55% of those with DS-ALL, in whom chromosomal rearrangements characteristic of non-DS-ALL are uncommon 4 . Moreover, CRLF2 alteration was observed exclusively in cases lacking translocations associated with ALL, suggesting that CRLF2 alteration is a potent leukemogenic event in the setting of trisomy 21 and may account in part for the up to 20-fold increased risk of developing ALL in children with DS 6, 17 . The associations of CRLF2 and JAK mutations and additional recurring cytogenetic alterations in DS-ALL (gain of chromosome X and deletion of 9p) 4 are also notable and suggest that these lesions cooperate in leukemogenesis. Notably, three of five subjects with PAR1 deletion and gain of chromosome X had evidence of two copies of the PAR1 deletion on FISH analysis ( Supplementary Fig. 4e-g ), suggesting that gain of X results in duplication and high-level expression of the P2RY8-CRLF2 fusion. Amplification of regions of chromosomal rearrangement resulting in gene fusion has previously been noted in acute leukemia, for example the NUP214-ABL1 translocation in T-lineage ALL 18 .
CRLF2 interacts with IL7R to form a heterodimeric receptor for the cytokine TSLP. TSLP-CRLF2 signaling has important roles in T-cell and 
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dendritic cell development, inflammation and allergic disease 7, 19 and promotes B-lymphoid proliferation, but may not be required for normal B-cell development 20, 21 . CRLF2 signaling results in downstream STAT5 phosphorylation 20, 22 and, for the human receptor, phosphorylation of JAK2 (ref. 20) . In contrast to myeloproliferative diseases, in which homozygous alteration of JAK2 Val617 is common 23 , the JAK alterations in B-progenitor ALL are usually heterozygous and do not occur at JAK2 Val617 (refs. 13, 15, 16) . The basis of the disease specificity of the different JAK alterations is unknown, but it has been suggested that the different JAK2 pseudokinase domain alterations facilitate interaction with different substrates and signaling pathways 13 . Detailed analysis of the transforming effect of mutant Jak alleles in Ba/F3 cells expressing P2RY8-CRLF2 and/or IL7R indicated that most Jak mutations are not transforming in the absence of CRLF2 overexpression (exceptions being the Jak2 mutation resulting in V617F and the homologous Jak1 mutation resulting in V658F; Supplementary Note and Supplementary Fig. 11 ). In contrast, the mutations most commonly observed in B-progenitor ALL (those at or near JAK2 R683) require coexpression of P2RY8-CRLF2 for transformation in this assay. Notably, transformation (as measured by the rate of cytokineindependent cell growth) was more marked with concomitant IL7R expression ( Supplementary Fig. 11 ). Moreover, coimmunoprecipitation experiments using 3×FLAG-tagged P2RY8-CRLF2 showed direct interaction of CRLF2 and phosphorylated Jak2 (Supplementary Fig. 13 ). Thus, our results indicate that aberrant signaling through the CRLF2-IL7R receptor, mediated by CRLF2 overexpression and Jak mutation, is a key event in B-lymphoid transformation. Consistent with this, in a recent study identifying CRLF2 rearrangement by FISH in human B-progenitor ALL, overexpression of CRLF2 promoted transformation and Stat5 phosphorylation of primary mouse lymphoid progenitors 11 . This study examined JAK2 exon 14 mutational status in a small cohort of individuals with DS-ALL (n = 24) and observed an association between CRLF2 rearrangement and JAK mutations 11 , further supporting cooperativity of these lesions in leukemogenesis.
As a substantial proportion of ALL cases with CRLF2 overexpression lack JAK mutations, mutational analysis of other kinases and mediators of JAK-STAT signaling is warranted. These findings also suggest that detection of increased CRLF2 expression will be a useful diagnostic strategy in ALL, and that JAK-STAT inhibition may be useful in the treatment of individuals with B-progenitor ALL with CRLF2 and JAK mutations.
MetHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession codes. Agilent array comparative genomic hybridization (CGH) data has been deposited in the NCBI's Gene Expression Omnibus under accession no. GSE16724. The P2RY8-CRLF2 mRNA sequence has been deposited in GenBank under accession no. GQ280263. SNP array data is available from the authors upon request.
Note: Supplementary information is available on the Nature Genetics website.

ONLINe MetHODS
Subjects and samples. We studied 272 children with B-progenitor ALL and 57 with T-lineage ALL treated at St. Jude Children's Research Hospital, including 22 with B-progenitor DS-ALL (Supplementary Table 1) . SNP array analysis of all except 14 of the individuals with DS-ALL has been previously reported 2, 3, 24, 25 . PAR1 alterations were examined in a validation cohort of 53 B-progenitor DS-ALL cases treated on or according to Children's Oncology Group protocols (n = 34) and the Associazione Italiana Ematologia de Oncologia Pediatrica (n = 19). All case samples were obtained with informed consent under protocols approved by institutional review board (US) or ethics committee (Italy). The study was approved by the institutional review boards of St. Jude Children's Research Hospital, Baylor College of Medicine and New York University.
SNP microarrays and array-CGH. SNP array analysis using 250K and 50K arrays or SNP 6.0 arrays (Affymetrix) was done as previously described 2,3,24-26 .
Array-based CGH. We conducted CGH using a 974,016-feature array (G4447A, Agilent) in two individuals with DS-ALL. The two-color array raw data were background-subtracted and normalized by locally weighted scatterplot smoothing using the Linear Models for Microarray Analysis 27 . The circular binary segmentation algorithm 28 was applied to normalized log 2 ratio data to identify copy-number alterations.
JAK1 and JAK2 sequencing. We sequenced JAK exons known to harbor mutations in B-progenitor ALL (JAK1 exons 13 and 14, and JAK2 exons 16, 20 and 21) 13-16 as previously described 16 (primers are listed in Supplementary  Table 6 ). Mutations were confirmed by repeat PCR and sequencing of tumor and normal DNA. The JAK2 mutation resulting in IR682RG (Down-SNP-#09) was confirmed by RT-PCR, cloning and sequencing of JAK2 exon 16.
Flow cytometric measurement of CRLF2 expression. Cryopreserved leukemic cells were stained with monoclonal antibodies, including phycoerythrinconjugated antibody to human TSLP receptor (clone 1A6; eBioscience); allophycocyanin-conjugated antibody to CD19, FITC-conjugated antibody to CD10 and peridinin chlorophyll protein-conjugated antibody to CD34 (all from BD Biosciences); and mouse IgG2a phycoerythrin-conjugated isotype control as a control for CRLF2 staining. Fc receptor binding was blocked using rabbit serum (Invitrogen). Data were acquired using a FACSCalibur flow cytometer (BD Biosciences) and analyzed with CellQuest Pro software. Blast cells were identified by Boolean gating using light-scattering properties of the blast cells (forward scatter vs. side scatter) and CD19 plus CD10 or CD34 positivity.
FISH detection of IGH@-CRLF2 translocation and PAR1 deletion. Interphase FISH analysis was done using cells stored in Carnoy fixative. Two probe mixtures were used: an IGH@-CRLF2 fusion probe mixture, in which BAC clones RP11-309M23 and RP11-261P4 flanking CRLF2 were labeled with Alexa Fluor 568 (red) and clone RP11-815P21 centromeric to IGH@ at 14q32.33 was labeled with Alexa Fluor 488 (green). In normal cells, the expected pattern is two green and two red signals (2G,2R). In cells containing the IGH@-CRLF2 fusion, the expected pattern is one green, two red and one fusion signal (1G,2R,1F). A second CRLF2 break-apart probe mixture was used, containing two BAC clones that flank the CRLF2 gene (RP11-309M23 labeled with Alexa Fluor 488, and RP11-74L17 labeled with Alexa Fluor 568). The signal pattern expected in interphase cells lacking CRLF2 rearrangement is two fusion signals (2F). In abnormal cells containing CRLF2 disruption, the expected pattern is one green, one red and one fusion signal (1G,1R,1F). All BAC clones were labeled using a standard nick translation protocol. Slide hybridization and washes were done using standard FISH protocols. The slides were then counterstained with the nuclear dye DAPI and analyzed with an Olympus BX61 microscope and CytoVision image analysis system (Applied Imaging). We scored 25-100 interphase cells for each probe mixture.
Mapping of genomic breakpoints of the PAR1 deletion. Genomic PCR using primers tiled outward from the limits of the PAR1 deletion was done on leukemic cell DNA. PCR products were purified and sequenced, and sequences were aligned to the hg18 reference genome using BLAT implemented in the UCSC genome browser.
RT-PCR and quantitative PCR. To amplify P2RY8-CRLF2 fusion transcripts, 0.5-1 µg of total leukemic cell RNA was reverse-transcribed and PCR-amplified using Phusion HF polymerase (New England Biolabs). Quantification of transcript levels of CRLF2 (using TaqMan gene expression assay Hs00277134_m1 from Applied Biosystems) and P2RY8-CRLF2 (using custom primers and probe) was done as previously described 2, 3 .
P2RY8-CRLF2 cloning, retroviral construct generation and Ba/F3 assays. Full-length P2RY8-CRLF2 was cloned into pGEM-T-Easy (Promega) and subcloned into the MSCV-IRES-eGFP retroviral vector. P2RY8-CRLF2 bearing a 3×FLAG tag at the C terminus of CRLF2 was PCR-amplified using primers C1459 and CRLF2 3×FLAG (Supplementary Table 6 ) and subcloned into MSCV-IRES-eGFP. Transduction of Ba/F3-IL7R cells with MSCV-P2RY8-CRLF2-3×FLAG-IRES-eGFP resulted in identical expression of CRLF2 (as assessed by quantitative PCR, western blotting and flow cytometry) to the non-FLAG-tagged construct, and comparable transformation and Jak-Stat activation after transduction with mutant Jak2.
MSCV-Jak2-IRES-luc2 vectors expressing wild-type or mutant Jak2 alleles were generated by subcloning the firefly luciferase cassette excised from the MSCV (Babe MCS)-IRES-luc2 retroviral vector into the previously described MSCV-Jak2-IRES-eGFP retroviral vectors 16 . The transforming effect of the MSCV-Jak2-IRES-luc2 vectors was confirmed by transducing Ba/F3-EpoR cells as previously described 16 . Retroviral supernatants were produced using ecotropic Phoenix packaging cells. Ba/F3-IL7R cells were generated by transducing Ba/F3 cells with MSCV-mIL7R-IRES-hCD4 and then cultured in medium supplemented with 10 ng/ml recombinant mouse IL7 (PeproTech). Ba/F3-IL7R cells were sequentially transduced with retroviral supernatants expressing P2RY8-CRLF2 and/or wild-type and mutant Jak2 alleles. Transduced cells were washed and grown in the absence of cytokine, and growth was quantified using a ViCell cell counter (Beckman Coulter). Expression of P2RY8-CRLF2 was assessed by flow cytometric measurement of GFP and CRLF2 expression. Expression of mouse IL7R was measured by flow cytometric measurement of human CD4 (using allophycocyaninconjugated antibody to human CD4; BD PharMingen). Expression of Jak2 alleles was measured using a Bright-Glo luciferase assay system (Promega). Western blotting was done as previously described 16 .
Drug exposure assays were done as previously described 16 . Ba/F3 cells were washed three times and plated at a density of 0.5 × 10 6 cells/ml in increasing concentrations of Jak inhibitor I (Calbiochem) or vehicle (dimethylsulfoxide). Cells were counted after 48 h of exposure to drug.
For immunoprecipitation assays, Jak-transduced Ba/F3-IL7R cells expressing 3×FLAG tagged P2RY8-CRLF2 were washed and cultured in the absence of cytokine. Ten million cells were washed and resuspended in lysis buffer (10× PBS with 0.5 M EDTA, 10% NP-40 and 50% glycerol) with protease inhibitors (Roche) and phosphatase inhibitors (Sigma-Aldrich). Lysates were passed through 21-gauge needles five times and centrifuged at 20,817g for 10 min at 4 C. Supernatants were incubated with washed protein-G agarose beads (Sigma-Aldrich) for 1 h at 4 °C. An aliquot of each precleared lysate was set aside to run as input. The remaining precleared lysates were incubated with washed anti-FLAG M2-agarose beads (Sigma-Aldrich) by rotating for 90 min. Lysates were incubated with 100 µg/ml 3×FLAG peptide (Sigma-Aldrich) to elute FLAG-bound proteins. LDS sample buffer (Invitrogen) was added to eluates, which were then boiled, electrophoresed and transferred to nitrocellulose membranes (Invitrogen). Membranes were probed with antibodies to Jak2, phosphorylated Jak2, Stat5 and phosphorylated Stat5 (Cell Signaling); CRLF2 (R&D Systems); and FLAG (Sigma-Aldrich). Antibody to PCNA (Santa Cruz Biotechnology) served as a loading control.
shRNA knockdown of CRLF2 in Ba/F3 cells. Five shRNAs targeting CRLF2 in the pLKO.1-puro lentiviral vector were tested (clones NM_022148.2-524s1c1 (524), NM_022148.2-181s1c1 (181), NM_022148.2-757s1c1 (757), NM_ 022148.2-286s1c1 (286) and NM_022148.2-689s1c1 (689); Sigma-Aldrich). Lentiviral particles for each CRLF2-specific shRNA and nontarget (scrambled) shRNA control vector (SHC002V) were produced by transient transfection of HEK293T cells with shRNA plasmid and the packaging plasmids CAG kGP1-1R (gag-pol), CAG4 RTR2 (rev-tat) and pHDMG (vesicular stomatitis virus-G envelope) 29 .
